|Mr. Gene G. Kinney||Pres, CEO & Director||820.88k||N/A||1969|
|Mr. Tran B. Nguyen||CFO & COO||598.02k||N/A||1974|
|Dr. Wagner M. Zago||Chief Scientific Officer||478.79k||N/A||1973|
|Ms. Carol D. Karp||Chief Regulatory Officer||574.99k||N/A||1953|
|Ms. Karin L. Walker||Chief Accounting Officer & Controller||N/A||N/A||1963|
Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegeneration. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Celgene Corporation to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.
Prothena Corporation plc’s ISS Governance QualityScore as of June 25, 2019 is 8. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 5; Compensation: 10.